PTC Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ptc Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:02.355 Ladies and gentlemen, thank you for standing by. 00:00:02.355 -- 00:00:07.583 Welcome to PTC Therapeutics' fourth quarter and full year 2025 earnings 00:00:07.583 -- 00:00:11.348 conference call. All participants are in a listen-only mode. 00:00:11.348 -- 00:00:14.273 After the presentation, there will be a question and answer session. 00:00:14.273 -- 00:00:19.240 Today's conference is being recorded. I would now like to turn the conference over to 00:00:19.240 -- 00:00:22.025 Ellen Cavallari, Head of Investor Relations. 00:00:22.025 -- 00:00:25.347 Please go ahead. 00:00:27.301 -- 00:00:32.488 Good afternoon, and thank you for joining us to discuss PTC Therapeutics' fourth quarter 00:00:32.488 -- 00:00:36.934 and year-end 2025 corporate update and financial results. 00:00:36.934 -- 00:00:39.978 I am joined today by our Chief Executive Officer, Dr. 00:00:39.978 -- 00:00:45.366 Matthew Klein, our Chief Business Officer, Eric Powles, and our Chief Financial Officer, 00:00:45.366 -- 00:00:50.513 Pierre Gravier. Today's call will include forward-looking statements based on our current 00:00:50.513 -- 00:00:55.518 expectations. These statements are subject to certain risks and uncertainties, and actual 00:00:55.518 -- 00:01:00.784 results may differ materially. Please review the slide posted on our Investor Relations 00:01:00.784 -- 00:01:05.430 website in conjunction with the call, which contains information about our forward-looking 00:01:05.430 -- 00:01:10.536 statements and our most recent annual report on Form 10-K filed with the 00:01:10.536 -- 00:01:15.902 SEC, as well as our other SEC filings for a detailed description of applicable 00:01:15.902 -- 00:01:20.678 risks and uncertainties that could cause our actual performance and ...